Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023

-Presentations include a late breaking poster from an ongoing Phase 1b study of ALG-000184 demonstrating multi-log reductions in HBsAg, DNA, and RNA levels in subjects dosed for up to 36 weeks-

-Data collectively highlight company’s progress advancing new potentially best-in-class compounds for liver disease-

SOUTH SAN FRANCISCO, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that the company is presenting several posters collectively highlighting data from its liver disease programs at the European Association for the Study of the Liver (EASL) Congress 2023, taking place in Vienna, Austria, June 21 – 24, 2023.

Notably, the Company’s late breaking poster (LBP-18) highlights promising emerging data from its ongoing Phase 1b study evaluating the oral capsid assembly modulator (CAM-E), ALG-000184. Specifically, a majority of HBeAg positive subjects dosed with 300 mg ALG-000184 + entecavir (ETV) for up to 36 weeks demonstrated time-dependent HBsAg reductions, with a maximum reduction of 2.0 log₁₀ IU/mL observed in week 36. Importantly, ALG-000184 continues to demonstrate a favorable safety and pharmacokinetic (PK) profile over these extended dosing durations.

Additionally, the Company is presenting results from its ongoing Phase 1 study evaluating single ascending doses of ALG-125755, a GalNAc-conjugated small interfering RNA, in virologically suppressed subjects with chronic hepatitis B (CHB). Specifically, subjects from cohorts 1 (50 mg, n=6) and cohort 2 (120 mg, n=6) demonstrated a sustained dose dependent reduction in HBsAg levels over 90 days. Evaluation of a third, higher dose cohort is ongoing. To date, all single ascending dose levels of ALG-125755 have been well tolerated in CHB subjects.

“We are excited to present emerging clinical data from our CHB portfolio of drug candidates at EASL,” said Lawrence Blatt, Ph.D., MBA, Chairman & CEO of Aligos Therapeutics. “The data presented highlights the progress we have made advancing new targeted therapies for multiple liver diseases. We look forward to presenting additional data from our robust pipeline of programs later this year.”

The presentations will be available on the Scientific Presentations and Conferences page on Aligos’ corporate website following the meeting. Presentation details are described below.